AI-Generated Summary

The Trump administration has announced a 100% tariff on imported branded and patented pharmaceutical products, effective October 1, with an exemption for companies establishing US manufacturing facilities. This policy aims to incentivize domestic production and reshape global pharmaceutical supply chains. Analysts warn the move could significantly increase healthcare costs for American consumers.

In a nutshell

This aggressive trade policy represents a significant shift towards pharmaceutical protectionism, compelling global pharma companies to re-evaluate their US market strategies and supply chain resilience. The tariffs could accelerate near-shoring trends while posing challenges for drug pricing and patient access.

Source: The Pioneer